Tonix Pharmaceuticals Holding Corp at ICR Virtual Conference Transcript
Good morning, everyone. Thank you for joining us today for the ICR conference. I'm Peter Vozzo, Managing Director at Westwicke ICR. And it's my pleasure to introduce Seth Lederman, President and Chief Executive Officer of Tonix Pharmaceuticals. Tonix is a clinical-stage biopharmaceutical company focused on central nervous system and immunology product candidates.
Seth is going to provide an overview of the company, which we will then follow with the Q&A session. (Conference Instructions)
With that, I'll turn it over to Seth.
Thank you, Peter, and thanks to the ICR organizers. It's a pleasure to be here. It's a very exciting time for Tonix. It's the best time in Tonix history. We have a lot of interesting news. And for those who haven't been following this story, we just announced a positive Phase 3 study in fibromyalgia in December.
So we are mid-Phase 3 in that program. We're recruiting in a second
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
